Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07008118 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT07008118: Recruiting Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
NCT07008118 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 120 participants, below the 137-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07008118, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG INCA035784
Study Locations (20)
Other
- Cliniques Universitaires Saint-Luc - Brussels
- Universitaire Ziekenhuizen Leuven - Leuven
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii - Mainz
- Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii - Bergamo
Texas
- South Austin Medical Center - Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood - Dallas
Arizona
- Mayo Clinic Hospital - Phoenix
California
- Stanford University - Palo Alto
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic-Florida - Jacksonville
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2029-12-14 |
| Phase | Phase 1 |
What NCT07008118 shows while recruiting
NCT07008118 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 137-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which INCA035784 is the first listed.
NCT07008118 names 20 study sites across 16 states, led by Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT07008118 about?
NCT07008118 is a clinical study titled "A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms". This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
What is the current status of trial NCT07008118?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-10-01. Estimated completion is 2029-12-14.
What conditions does trial NCT07008118 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT07008118?
The interventions under investigation include: INCA035784 (DRUG).
Who is sponsoring clinical trial NCT07008118?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07008118 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07008118's enrollment target sits among peer trials
120 5th of 8 higher than 4 of 8 other Myeloproliferative Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
ACTIVE NOT RECRUITING · Phase 1
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI